Mensacarcin exhibits potent cytostatic and cytotoxic effects against melanoma cells, inducing rapid apoptotic cell death through mitochondrial dysfunction and activation of caspase-dependent apoptosis pathways; it shows broad-spectrum growth inhibition across NCI-60 cancer cell lines with selective cytotoxicity toward melanoma; it can be used as a cytotoxic payload in antibody-drug conjugates (ADCs) and functions as an antibiotic.